Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Breast Cancer

  Free Subscription


Articles published in Eur J Cancer

Retrieve available abstracts of 59 articles:
HTML format
Text format



Single Articles


    March 2017
  1. VERMEULEN MA, Slaets L, Cardoso F, Giordano SH, et al
    Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.
    Eur J Cancer. 2017 Mar 11. pii: S0959-8049(17)30726.
    PubMed     Text format     Abstract available


  2. GIACCHETTI S, Hamy AS, Delaloge S, Brain E, et al
    Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status.
    Eur J Cancer. 2017;75:323-332.
    PubMed     Text format     Abstract available


  3. RIET FG, Fayard F, Arriagada R, Santos MA, et al
    Preoperative radiotherapy in breast cancer patients: 32 years of follow-up.
    Eur J Cancer. 2017;76:45-51.
    PubMed     Text format     Abstract available


    February 2017
  4. AMBATIPUDI S, Horvath S, Perrier F, Cuenin C, et al
    DNA methylome analysis identifies accelerated epigenetic ageing associated with postmenopausal breast cancer susceptibility.
    Eur J Cancer. 2017;75:299-307.
    PubMed     Text format     Abstract available


  5. DUFFY MJ, Harbeck N, Nap M, Molina R, et al
    Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM).
    Eur J Cancer. 2017;75:284-298.
    PubMed     Text format     Abstract available


  6. VAN KAMPEN RJ, Ramaekers BL, Lobbezoo DJ, de Boer M, et al
    Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium.
    Eur J Cancer. 2017 Feb 25. pii: S0959-8049(17)30088.
    PubMed     Text format     Abstract available


  7. YOUSSEF MM, Cameron D, Olsen S, Ferguson D, et al
    Does axillary lymph node dissection impact survival in patients with breast cancer and isolated tumour cells or micrometastasis in sentinel node?
    Eur J Cancer. 2017;75:167-168.
    PubMed     Text format    


  8. PULITI D, Bucchi L, Mancini S, Paci E, et al
    Advanced breast cancer rates in the epoch of service screening: The 400,000 women cohort study from Italy.
    Eur J Cancer. 2017;75:109-116.
    PubMed     Text format     Abstract available


  9. MAKAMA M, Drukker CA, Rutgers EJ, Slaets L, et al
    An association study of established breast cancer reproductive and lifestyle risk factors with tumour subtype defined by the prognostic 70-gene expression signature (MammaPrint(R)).
    Eur J Cancer. 2017;75:5-13.
    PubMed     Text format     Abstract available


    January 2017
  10. FREOUR T, Barriere P, Masson D
    Anti-mullerian hormone levels and evolution in women of reproductive age with breast cancer treated with chemotherapy.
    Eur J Cancer. 2017;74:1-8.
    PubMed     Text format     Abstract available


  11. CARDOSO F, Cataliotti L, Costa A, Knox S, et al
    European Breast Cancer Conference manifesto on breast centres/units.
    Eur J Cancer. 2017;72:244-250.
    PubMed     Text format     Abstract available


    December 2016
  12. GENRE L, Roche H, Varela L, Kanoun D, et al
    External validation of a published nomogram for prediction of brain metastasis in patients with extra-cerebral metastatic breast cancer and risk regression analysis.
    Eur J Cancer. 2016;72:200-209.
    PubMed     Text format     Abstract available


  13. TOUATI N, Tryfonidis K, Caramia F, Bonnefoi H, et al
    Correlation between severe infection and breast cancer metastases in the EORTC 10994/BIG 1-00 trial: Investigating innate immunity as a tumour suppressor in breast cancer.
    Eur J Cancer. 2016;72:95-102.
    PubMed     Text format     Abstract available


  14. LIU CY, Huang TT, Huang CT, Hu MH, et al
    EGFR-independent Elk1/CIP2A signalling mediates apoptotic effect of an erlotinib derivative TD52 in triple-negative breast cancer cells.
    Eur J Cancer. 2016;72:112-123.
    PubMed     Text format     Abstract available


  15. O'BRYAN S, Dong S, Mathis JM, Alahari SK, et al
    The roles of oncogenic miRNAs and their therapeutic importance in breast cancer.
    Eur J Cancer. 2016;72:1-11.
    PubMed     Text format     Abstract available


    November 2016
  16. SUTHERLAND S, Miles D, Makris A
    Use of maintenance endocrine therapy after chemotherapy in metastatic breast cancer.
    Eur J Cancer. 2016 Nov 12. pii: S0959-8049(16)32450.
    PubMed     Text format     Abstract available


  17. MA Y, Zhang S, Zang L, Li J, et al
    Combination of shear wave elastography and Ki-67 index as a novel predictive modality for the pathological response to neoadjuvant chemotherapy in patients with invasive breast cancer.
    Eur J Cancer. 2016;69:86-101.
    PubMed     Text format     Abstract available


  18. HEIL J, Schaefgen B, Sinn P, Richter H, et al
    Can a pathological complete response of breast cancer after neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy?
    Eur J Cancer. 2016;69:142-150.
    PubMed     Text format     Abstract available


  19. OULDAMER L, Bendifallah S, Chas M, Boivin L, et al
    Intrinsic and extrinsic flaws of the nomogram predicting bone-only metastasis in women with early breast cancer: An external validation study.
    Eur J Cancer. 2016;69:102-109.
    PubMed     Text format     Abstract available


  20. MILES D, Cameron D, Bondarenko I, Manzyuk L, et al
    Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation.
    Eur J Cancer. 2016 Nov 4. pii: S0959-8049(16)32470.
    PubMed     Text format     Abstract available


    October 2016
  21. JERZAK KJ, Pritchard KI
    The 21-gene recurrence score assay in node-negative early breast cancer: Prognostic, predictive or presumptuous?
    Eur J Cancer. 2016;68:173-175.
    PubMed     Text format    


    September 2016
  22. ABDEL-QADIR H, Amir E, Fischer HD, Fu L, et al
    The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer.
    Eur J Cancer. 2016;68:11-21.
    PubMed     Text format     Abstract available


  23. BOUDIN L, Chabannon C, Sfumato P, Sabatier R, et al
    Corrigendum to "Immunohistochemical subtypes predict survival in metastatic breast cancer receiving high-dose chemotherapy with autologous haematopoietic stem cell transplantation" [Eur J Cancer 57 (April 2016) 118-126].
    Eur J Cancer. 2016 Sep 24. pii: S0959-8049(16)32402.
    PubMed     Text format    


  24. KILLANDER F, Karlsson P, Anderson H, Mattsson J, et al
    No breast cancer subgroup can be spared postoperative radiotherapy after breast-conserving surgery. Fifteen-year results from the Swedish Breast Cancer Group randomised trial, SweBCG 91 RT.
    Eur J Cancer. 2016;67:57-65.
    PubMed     Text format     Abstract available


    August 2016
  25. NAGRANI R, Mhatre S, Rajaraman P, Soerjomataram I, et al
    Central obesity increases risk of breast cancer irrespective of menopausal and hormonal receptor status in women of South Asian Ethnicity.
    Eur J Cancer. 2016;66:153-161.
    PubMed     Text format     Abstract available


  26. ALBANELL J, Svedman C, Gligorov J, Holt SD, et al
    Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor-positive, human epidermal growth factor receptor 2-negative early-stage breas
    Eur J Cancer. 2016;66:104-113.
    PubMed     Text format     Abstract available


  27. TATE SC, Andre V, Enas N, Ribba B, et al
    Early change in tumour size predicts overall survival in patients with first-line metastatic breast cancer.
    Eur J Cancer. 2016;66:95-103.
    PubMed     Text format     Abstract available


  28. AMMITZBOLL G, Sogaard K, Karlsen RV, Tjonneland A, et al
    Physical activity and survival in breast cancer.
    Eur J Cancer. 2016;66:67-74.
    PubMed     Text format     Abstract available


    June 2016
  29. VON MINCKWITZ G, Rezai M, Tesch H, Huober J, et al
    Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29).
    Eur J Cancer. 2016;64:12-21.
    PubMed     Text format     Abstract available


  30. MARGUET S, Mazouni C, Ramaekers BL, Dunant A, et al
    European cost-effectiveness study of uPA/PAI-1 biomarkers to guide adjuvant chemotherapy decisions in breast cancer.
    Eur J Cancer. 2016;63:168-179.
    PubMed     Text format     Abstract available


  31. AALDERS KC, van Bommel AC, van Dalen T, Sonke GS, et al
    Contemporary risks of local and regional recurrence and contralateral breast cancer in patients treated for primary breast cancer.
    Eur J Cancer. 2016;63:118-126.
    PubMed     Text format     Abstract available


  32. IGNATIADIS M, Rack B, Rothe F, Riethdorf S, et al
    Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trial.
    Eur J Cancer. 2016;63:97-104.
    PubMed     Text format     Abstract available


    May 2016
  33. JACKISCH C, Hegg R, Stroyakovskiy D, Ahn JS, et al
    HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up.
    Eur J Cancer. 2016;62:62-75.
    PubMed     Text format     Abstract available


  34. SIA J, Moodie K, Bressel M, Lau E, et al
    A prospective study comparing digital breast tomosynthesis with digital mammography in surveillance after breast cancer treatment.
    Eur J Cancer. 2016;61:122-127.
    PubMed     Text format     Abstract available


  35. MACDONALD KV, Bombard Y, Deal K, Trudeau M, et al
    The influence of gene expression profiling on decisional conflict in decision making for early-stage breast cancer chemotherapy.
    Eur J Cancer. 2016;61:85-93.
    PubMed     Text format     Abstract available


  36. GOODWIN RA, Jamal R, Booth CM, Goss PE, et al
    Prognostic and predictive effects of diabetes, hypertension, and coronary artery disease among women on extended adjuvant letrozole: NCIC CTG MA.17.
    Eur J Cancer. 2016;58:97-103.
    PubMed     Text format     Abstract available


  37. HOUVENAEGHEL G, Classe JM, Garbay JR, Giard S, et al
    Survival impact and predictive factors of axillary recurrence after sentinel biopsy.
    Eur J Cancer. 2016;58:73-82.
    PubMed     Text format     Abstract available


    April 2016
  38. COOMBES RC, Kilburn LS, Tubiana-Mathieu N, Olmos T, et al
    Epirubicin dose and sequential hormonal therapy-Mature results of the HMFEC randomised phase III trial in premenopausal patients with node positive early breast cancer.
    Eur J Cancer. 2016;60:146-153.
    PubMed     Text format     Abstract available


  39. AFTIMOS P, Polastro L, Ameye L, Jungels C, et al
    Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial.
    Eur J Cancer. 2016;60:117-124.
    PubMed     Text format     Abstract available


  40. LOVE RR, Hossain SM, Hussain MM, Mostafa MG, et al
    Luteal versus follicular phase surgical oophorectomy plus tamoxifen in premenopausal women with metastatic hormone receptor-positive breast cancer.
    Eur J Cancer. 2016;60:107-116.
    PubMed     Text format     Abstract available


  41. GAHLAUT R, Bennett A, Fatayer H, Dall BJ, et al
    Effect of neoadjuvant chemotherapy on breast cancer phenotype, ER/PR and HER2 expression - Implications for the practising oncologist.
    Eur J Cancer. 2016;60:40-48.
    PubMed     Text format     Abstract available


    March 2016
  42. LLOMBART-CUSSAC A, Ramos M, Dalmau E, Garcia-Saenz JA, et al
    Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy. Results from the Spanish Breast Cancer Group/2009-02 study.
    Eur J Cancer. 2016;58:122-129.
    PubMed     Text format     Abstract available


    February 2016
  43. BOUDIN L, Chabannon C, Sfumato P, Sabatier R, et al
    Immunohistochemical subtypes predict survival in metastatic breast cancer receiving high-dose chemotherapy with autologous haematopoietic stem cell transplantation.
    Eur J Cancer. 2016;57:118-126.
    PubMed     Text format     Abstract available


    January 2016
  44. STRASSER-WEIPPL K, Horick N, Smith IE, O'Shaughnessy J, et al
    Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy.
    Eur J Cancer. 2016;56:85-92.
    PubMed     Text format     Abstract available


  45. LINTERMANS A, Van Asten K, Jongen L, Van Brussel T, et al
    Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients.
    Eur J Cancer. 2016;56:31-36.
    PubMed     Text format     Abstract available


  46. PARADA H JR, Wolff MS, Engel LS, Eng SM, et al
    Polychlorinated biphenyls and their association with survival following breast cancer.
    Eur J Cancer. 2016;56:21-30.
    PubMed     Text format     Abstract available


  47. CRESTI N, Lee J, Rourke E, Televantou D, et al
    Genetic variants in the HER2 gene: Influence on HER2 overexpression and loss of heterozygosity in breast cancer.
    Eur J Cancer. 2016;55:27-37.
    PubMed     Text format     Abstract available


    December 2015
  48. MILIC M, Foster A, Rihawi K, Anthoney A, et al
    'Tablet burden' in patients with metastatic breast cancer.
    Eur J Cancer. 2015;55:1-6.
    PubMed     Text format     Abstract available


  49. TRYFONIDIS K, Basaran G, Bogaerts J, Debled M, et al
    A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066
    Eur J Cancer. 2015;53:144-154.
    PubMed     Text format     Abstract available


  50. LAMBERTINI M, Anserini P, Del Mastro L
    Is it safe to perform a controlled ovarian stimulation for assisted reproduction in young breast cancer survivors?
    Eur J Cancer. 2015 Dec 17. pii: S0959-8049(15)00916.
    PubMed     Text format    


  51. MARME F, Lederer B, Blohmer JU, Costa SD, et al
    Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy.
    Eur J Cancer. 2015;53:65-74.
    PubMed     Text format     Abstract available


  52. PIZOT C, Boniol M, Mullie P, Koechlin A, et al
    Physical activity, hormone replacement therapy and breast cancer risk: A meta-analysis of prospective studies.
    Eur J Cancer. 2015;52:138-154.
    PubMed     Text format     Abstract available


  53. GOLDRAT O, Demeestere I, Azim HA
    Is it safe to perform a controlled ovarian stimulation for assisted reproduction in young breast cancer survivors?
    Eur J Cancer. 2015 Dec 8. pii: S0959-8049(15)00915.
    PubMed     Text format    


    November 2015
  54. VRIENS BE, de Vries B, Lobbes MB, van Gastel SM, et al
    Ultrasound is at least as good as magnetic resonance imaging in predicting tumour size post-neoadjuvant chemotherapy in breast cancer.
    Eur J Cancer. 2015;52:67-76.
    PubMed     Text format     Abstract available


  55. ROSSI M, Carioli G, Bonifazi M, Zambelli A, et al
    Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival.
    Eur J Cancer. 2015;52:41-49.
    PubMed     Text format     Abstract available


  56. KHARAZMI E, Forsti A, Sundquist K, Hemminki K, et al
    Survival in familial and non-familial breast cancer by age and stage at diagnosis.
    Eur J Cancer. 2015;52:10-18.
    PubMed     Text format     Abstract available


  57. ZUCCHINI G, Armstrong AC, Wardley AM, Wilson G, et al
    A phase II trial of low-dose estradiol in postmenopausal women with advanced breast cancer and acquired resistance to aromatase inhibition.
    Eur J Cancer. 2015 Nov 17. pii: S0959-8049(15)00845.
    PubMed     Text format     Abstract available


  58. FRANCIS A, Thomas J, Fallowfield L, Wallis M, et al
    Addressing overtreatment of screen detected DCIS; the LORIS trial.
    Eur J Cancer. 2015;51:2296-303.
    PubMed     Text format     Abstract available


    September 2015
  59. PONZONE R, Maggiorotto F, Carabalona S, Rivolin A, et al
    MRI and intraoperative pathology to predict nipple-areola complex (NAC) involvement in patients undergoing NAC-sparing mastectomy.
    Eur J Cancer. 2015;51:1882-9.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: